IGI Logo

* IPM exhibited a growth of 16.6% YoY in Jun’22 v/s a 3.3% YoY decline in May’22. The growth in Jun’21 was 14.3%.

* Gynecology/Dermatology/Pain/Gastrointestinal were major drivers of IPM growth, up 33.2%/23.9%/23.1%/21.4% YoY.

* Growth was dragged lower by a 6.1% YoY decline in vaccines.

For the quarter-ending Jun’22, volumes/new products decline YoY, dragging IPM growth

*  For the quarter-ending Jun’22, IPM grew 2.1% YoY.

* Prices grew 5.4%, while volumes/new products declined by 2.5%/0.8% YoY.

On a MAT basis, Respiratory, Pain/Analgesics, Gynecology, and Gastrointestinal drive YoY growth for the 12-month ending Jun’22

* On a MAT basis, industry growth came in at 6.6% YoY. ? Respiratory/Pain/Gynecology grew 17.5%/16%/14.4% YoY.

* Vaccines/Anti-Infectives sales declined by 19.8%/2.8% YoY, impacting overall growth.

* Respiratory posted a YoY decline in Apr’22 and May’22, but the same has picked up with a 16.4% growth in Jun’22.

Mankind, Ipca, and Intas are the top performers in Jun’22

*  Among the top 20 corporates, Mankind Pharma (+41% YoY), Ipca Laboratories (+32.7% YoY), Intas Pharmaceuticals (+27.8% YoY), GlaxoSmithKline Pharmaceuticals (+21.9% YoY), Sun Pharmaceutical Industries (+21.7% YoY), and Torrent Pharmaceuticals (+21.7% YoY) grew notably higher than IPM growth.

To Read Complete Report & Disclaimer Click Here

For More Motilal Oswal Securities Ltd Disclaimer http://www.motilaloswal.com/MOSLdisclaimer/disclaimer.html SEBI Registration number is INH000000412

Above views are of the author and not of the website kindly read disclaimer